News and Events

Trefoil Therapeutics presents accelerated healing of corneal endothelial lesions by engineered fibroblast growth factor at ARVO 2020.

Experienced clinical development executive to lead the TTHX1114 clinical study in corneal endothelial disease.

AGC selected based on their proven cGMP capabilities as a manufacturer of protein based therapeutics.

Lead candidate TTHX1114 will advance to IND and clinical study in corneal endothelial disease in early 2020.

As the company’s eFGF-1 platform moves forward, Dr. McGraw brings significant high-level experience in development and commercialization.

Hatteras Venture Partners leads round which provides funding to reach IND filing for novel corneal endothelial dystrophy therapy.

TRND Award Will Accelerate the Development of a New Therapy for Fuchs Dystrophy

Expands Research from Endothelial to Epithelial Cell Regeneration

Engineered FGF-1 Derivatives Stimulate Proliferation of Corneal Endothelial Cells

Development Program to Focus on the Treatment of Corneal Dystrophies